GlobeNewswire

Nexstim Has Received Three New NBS System Orders

Share

Press release, Helsinki, 22 December 2020 at 9.30 am (EET)

Nexstim Has Received Three New NBS System Orders

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received three new NBS system orders in December.

One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus® nTMS features will replace the hospital’s older NBS system.

Nexstim NBS systems with SmartFocus® nTMS are mainly used for neurosurgical diagnostics to provide information on tumour’s or on other lesion’s location in relation to the essential functions and their connections in the patient’s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.

Mikko Karvinen, CEO of Nexstim, said: “We are delighted to welcome a new NBS System user from Spain to our SmartFocus® nTMS community.In addition, receiving NBS System upgrade orders show that our existing users want to use our technology also in the future — there is a clear need for it. To fulfil that need we want to offer our customers the latest technology innovations to help them to diagnose and treat patients with difficult brain disorders.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Participation Notification by Blackrock Inc.27.1.2021 08:30:00 CETPress release

Participation notification by Blackrock Inc. Brussels, 27 January 2021, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalJanuary 21, 20212.94%0.09%3.03%January 22, 20213.03%0.09%3.12% The latest notification, dated January 25, 2021, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: January 22, 2021Threshold of direct voting rights crossed: 3% upwardsDenominator: 105,876,416Additional information: The disclosure obligation arose

Statkraft og Aker Offshore Wind utforsker prosjektmuligheter i Norge27.1.2021 08:01:03 CETPressemelding

(Oslo, 27. januar, 2021) Statkraft, Europas største fornybarprodusent, Aker Offshore Wind og Aker Horizons har signert en samarbeidsavtale for å utforske prosjektmuligheter for havvind i Norge. Selskapene vil forene sine sterke og komplementære ferdigheter og ekspertise for sammen å utforske mulighetene for å utvikle, drifte og levere kraft fra kommersielle fullskala havvindparker i Norge. Norske myndigheter annonserte i fjor at de ville åpne for søknader om utvikling av havvind på to områder i Nordsjøen, nærmere bestemt Utsira Nord og Sørlige Nordsjø II. Samarbeidspartnerne vil utforske muligheten for bunnfast havvind på Sørlige Nordsjø II (SN2), hvor selskapene vil etablere en felles prosjektgruppe, 50/50 delt mellom Aker Offshore Wind og Statkraft for felles utarbeidelse og innlevering av melding, samt videre utvikling av prosjektet. Statkrafts ambisjon er å bli et verdensledende selskap innen fornybar energi og har som ledd i dette satset betydelig på utbygging av sol- og vindkraft

Statkraft and Aker Offshore Wind explore project opportunities in Norway27.1.2021 08:01:03 CETPress release

(Oslo, Norway – January 27, 2021) Statkraft, Europe’s largest renewable energy producer, Aker Offshore Wind and Aker Horizons have signed a cooperation agreement to explore offshore wind project opportunities in Norway. The companies will combine their strong, complementary skills and expertise to work together to explore the possibility to develop, operate and deliver power from commercial scale offshore wind facilities in Norway. Last year, the Norwegian government announced it will open for applications for licenses for the development of wind power in two areas in the North Sea, namely “Utsira Nord” and “Sørlige Nordsjø II”. The cooperation will explore the opportunity for bottom-fixed offshore wind at Sørlige Nordsjø II (“SN2”), for which the companies will establish an integrated project team, 50/50 split between Aker Offshore Wind and Statkraft, for joint preparation and submission of an acreage application and further development activities. Statkraft’s ambition is to be a worl

Ökad omsättning och lönsamhet för 2020 under ett utmanande fjärde kvartal27.1.2021 08:00:00 CETPressemelding

Januari - december Nettoomsättningen ökade med +0,8 procent till 310,1 (307,6) mkr (+3 procent i lokala valutor)Rörelseresultatet uppgick till 28,6 (6,2) mkr Rörelsemarginalen uppgick till 9,1 (2,0) procentResultat efter skatt uppgick till 16,3 (4,9) mkrResultat per aktie före/efter utspädning uppgick till 0,88 (0,28) krKassaflöde från den löpande verksamheten uppgick till 52,0 (17,7) mkrLikvida medel uppgick vid periodens utgång till 101,2 (63,9) mkr Fjärde kvartalet Nettoomsättningen minskade med -20,6 procent till 66,7 (84,0) mkr, (-14,5 procent i lokala valutor)Rörelseresultatet uppgick till -4,0 (3,7) mkr Rörelsemarginalen uppgick till -6,0 (4,4) procentResultat efter skatt uppgick till -7,0 (1,3) mkrResultat per aktie uppgick till -0,38 (0,07) krKassaflöde från den löpande verksamheten uppgick till 47,2 (10,5) mkr VD's Kommentar 2020, som vi nu lämnat bakom oss, har utan tvekan varit ett av de mest omvälvande åren under min tid som VD för MSAB. Pandemin har definierat helt nya oc

Increased sales and profitability in 2020 during a challenging fourth quarter27.1.2021 08:00:00 CETPress release

January - December Net sales increased +0.8 percent to SEK 310.1 (307.6) million (+3 percent in local currencies).EBIT was SEK 28.6 (6.2) million.The EBIT margin was 9.1 (2.0) percent.Profit after tax amounted to SEK 16.3 (4.9) million.Earnings per share before/after dilution amounted to SEK 0.88 (0.28).Cash flow from operating activities amounted to SEK 52.0 (17.7) million.Cash and cash equivalents at the end of the period amounted to SEK 101.2 (63.9) million. Fourth quarter Net sales declined -20.6 percent to SEK 66.7 (84.0) million (-14.5 percent in local currencies).EBIT was SEK -4.0 (3.7) million.The EBIT margin was -6.0 (4.4) percent.Profit after tax amounted to SEK -7.0 (1.3) million.Earnings per share amounted to SEK -0.38 (0.07).Cash flow from operating activities amounted to SEK 47.2 (10.5) million. Comments from the CEO Looking at 2020 in the rear-view mirror, I can say that it has without doubt been one of my stormiest years as CEO for MSAB. The pandemic has defined an enti

Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Nederländerna27.1.2021 08:00:00 CETPressemelding

27 januari 2021 Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Nederländerna Immunicum AB (publ; IMMU.ST) meddelar idag att de aktiviteter inom forskning och processutveckling som bolaget driver i egen regi kommer att flytta till en ny anläggning i Leiden Bio Science Park i Nederländerna. Bolaget har ingått avtal om ett långtidshyreskontrakt med entreprenören Kadans Science Partner avseende cirka 1 100 m2 laboratorie- och kontorsyta i Plus Ultra Leiden, en ny byggnad som är under konstruktion. Vidare har Immunicum option att hyra ytterligare 1 100 m2 för att ytterligare stödja bolagets framtida tillväxt., Den nya anläggningen, som förväntas vara i drift år 2022, kommer att fungera som Immunicums nav för forskning och utveckling. ”Denna toppmoderna anläggning i en av Europas hetaste platser för forskning inom life science är en integrerad del av vår bolagsstrategi som gör det möjligt för oss att snabbt och kostnadseffektivt f

Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands27.1.2021 08:00:00 CETPress release

Press Release 27 January 2021 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum’s core research and development hub. “This state-of-the-art facility in one of Europe’s most vibrant life sciences research communities is an integral part of our corporate strategy as it will enable us to rapidly and cost-effectively continue